Don't you negotiate scope and salary at the beginning of hiring term?
Not a bid deal when you've made million upon millions off of selling shares earlier in secondary offerings. Would anyone be surprised to see those shares wind up in a another secondary or flipped?
Agreed- lame response couldn't agree on scope of responsibilities? Seems enigmatic at best a scenario which should have been able to be resolved without departure. NP- it would appear our a little zealous in your headlines and making you appear as a short vs someone who is purely objective in his messages.
Once and for all are you a short? I have no problem with your comments, as its hard to ignore the chronic problems at REED's. As I've learned-painfully along with other shareholders invested with REED's, its a story about great products and the drawback being management. The solution is obvious: get capable hands on management in place, and still mix your brews, partner with a mighty force or find bidders!!
Sorry to see you leave-
RGB has been selling for years at a premium and w/o profit. Private label is worthless to an acquirer. Kombucha has big distribution, after two years no real sales numbers (remember komb is selling in major grocery and at big premium to CSD price). Best hope here is clear out the dead wood, find partnerships or auction it off.
VI see no need to raise cash= Insiders made out great selling stock along the way and so shareholders are hung to dry. Where are the shareholder yachts?
Part of the obvious- The Society for Information Display's annual Symposium at Display Week running from June 1-6, 2014,
Given, that with EMAN's is a leading supplier of OLED display to military means this degree of quality is tested. And it would seem illogical for GOOGLE to use a non-tested French company without broad activities? If EMAN proves it can direct pattern (how far that day is away-nobody knows) and get that SNU to fire with consistency, then certainly this company's share price will undoubtedly go higher in price. Still in proof stage!!
Vote why you think MITK stock is down under (AUS investors are allowed to vote on this matter)?
I believe the stock resistance to antidepressants is caused by the USAA lawsuit and ability to uphold photo capture patent?
I had a similar situation: buy at $5 got impatient sold and it went to $112. However, I got revenge on Monster or Hansen. Eating up a component source is the way APPL/SAMSUNG and others are doing it.
Yea-Its scary to think how the store will run itself without a much needed chaparone? When you see the best asset managers I.e Driehaus and others spend time in the stock and then leave without a forwarding address, their departure is a sky painting festival, which reads "seek shelter of cash".
Unfortunately, you are a short and probably on the right side of the trade. Six months to jog around the bases and not get any counted runs (FIND a solid replacement with pedigree in tow I.e Wharton or a street wise guy like Kevin Klock, CEO of Talking Rain. Shareholders were dumb and should have somehow sought outside help to get a steward for the company vs old guard.
The consensus used to be a suitor would pay up for the company from a multiple of sales perspective. If you listen to the last cc, as for valuation, it sounded like the company was a piece of bait flung off a fishing pier vs being offered on a big appetite plate (dressed up for sale). The recent sales numbers takes us back to a level not seen since Mar-2013. One must not be spare on thought/reflection at this time with respect to investment thesis. Being the number one drink in organic channels means nothing if you never scale and reach profitability. And Komubucha sales are just a mix of oil and water at this juncture. You will probably see the company go on the auction block (as for a premium- that's no guarantee). What is certain is the captain needs to find capable people to keep him below ship, while they themselves run the company above board, in a business manner vs high-school musical II
The name calling is an indication of invalid argument and immaturity. Your value is your word and for most of us, we realize nothing than the obvious lies your promoting.
What does anyone see in the ASTM acquiring Sanofi's assets which compete with OSIR, and does the low price take reflect demand for stem-cell related products or just quality of products being offered?
ased on our back-of-the-envelope calculations, Aastrom could see $5-10 million in operating profits from CTRM in 2015
In retrospect- the tech playing field is being more defined by owning or buying out the supplier vs avail sourcing to the world I.e your competitors.